VYGR
Voyager Therapeutics Inc
2.90$
-8.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1,895.8% | -17.4% | -2.7% | -4.0% | +100.4% | -26.3% | -25.9% | -17.8% | +120.4% | +11.9% | -35.8% | |
| – | +2,243.8% | -8.7% | -3.9% | -5.4% | +87.5% | -35.1% | -30.9% | -8.9% | +156.8% | -13.4% | -26.8% | |
| – | +345.0% | +17.0% | -13.9% | +48.6% | +83.6% | +21.4% | +12.4% | -15.7% | -30.5% | +3.7% | -8.5% | |
| – | +3,089.0% | -22.3% | -3.1% | -7.8% | +80.7% | -35.7% | -26.8% | -10.3% | +94.3% | +15.5% | -26.3% | |
| – | – | +460.3% | -94.7% | +64.8% | +9,203.0% | -57.2% | -90.7% | -14.6% | +13,116.7% | -94.7% | -60.8% | |
| – | – | – | +21.4% | +176.4% | -56.9% | +215.6% | -75.4% | -54.4% | -100.0% | – | – | |
| – | +15.3% | +144.1% | +30.3% | +24.2% | +263.8% | -45.3% | -13.8% | -18.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +483.5% | -11.2% | -6.0% | +159.0% | +95.5% | -58.0% | -7.9% | +1.6% | +14.6% | -18.9% | -39.8% | |
| – | +867.3% | -42.3% | +15.2% | +99.2% | +140.0% | -64.8% | +90.5% | +42.4% | -11.1% | -22.8% | -46.7% | |
| – | – | – | – | – | – | +31.5% | +32.7% | -49.2% | +13.0% | +125.8% | +8.5% | |
| – | -60.6% | -10.1% | +85.5% | +1.8% | +292.1% | -84.4% | -9.5% | +347.0% | -37.5% | +149.1% | +25.5% | |
| – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | +14,614.9% | -19.6% | -1.4% | -65.4% | +114.3% | +55.1% | -38.4% | -37.9% | +300.4% | +26.8% | -34.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -71.5% | +503.7% | +5.9% | +19.6% | +12.0% | +4.0% | +0.9% | +1.8% | +16.2% | +29.4% | +1.8% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.